Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
MWN-AI** Summary
CeriBell, Inc. (Nasdaq: CBLL), a medical technology company focused on serious neurological conditions, announced its financial results for the fourth quarter and the full year ended December 31, 2025, revealing significant growth and several regulatory milestones. For Q4 2025, the company reported total revenue of $24.8 million, representing a 34% increase year-over-year from $18.5 million in Q4 2024. The full year revenue hit $89.1 million, a 36% growth from $65.4 million in 2024.
The impressive revenue growth was driven by the expansion into new accounts and increased adoption among existing clients. CeriBell ended the year with 647 active accounts and reported strong gross margins of 87% for the fourth quarter and 88% for the full year. However, operating expenses rose to $36.2 million in Q4 2025, up from $29.1 million in Q4 2024, largely due to investments in the commercial team and legal expenses, leading to a net loss of $13.5 million for Q4 2025, although this was slightly lower on a per-share basis compared to the previous year.
CeriBell also reached several critical regulatory milestones, including FDA clearances for its innovative continuous monitoring solutions for delirium and the first FDA-cleared seizure detection algorithm for neonates. Additionally, the company received Breakthrough Device Designation for its LVO stroke detection system.
Looking ahead, CeriBell anticipates a revenue growth of approximately 25% to 29% for 2026, projecting total revenue between $111 million and $115 million. The firm's CEO, Jane Chao, expressed confidence that their achievements will facilitate continued growth and the long-term vision of making EEG monitoring a vital sign for patients.
MWN-AI** Analysis
Ceribell, Inc. has reported strong growth in its latest financial results for the fourth quarter and full year of 2025, with total revenues reaching $24.8 million for Q4 and $89.1 million for the year, representing year-over-year increases of 34% and 36%, respectively. The robust growth can be attributed to a broadened customer base and enhanced adoption rates within existing accounts, particularly after significant FDA clearances that position Ceribell’s technology as a leader in the neurological diagnostic space.
Despite the impressive revenue growth, investors should take note of a marked increase in operating expenses, which surged by 24% in Q4 and 42% for the full year, primarily due to investments in the commercial organization and an uptick in headcount. This heightened expenditure contributed to a net loss of $13.5 million in Q4 and over $53 million for the year, a key element to consider for potential investors. While the company maintains a substantial cash reserve of $159.3 million, it is essential to monitor cash flow management closely as Ceribell continues to invest heavily to fuel its growth trajectory.
Looking forward, Ceribell has projected revenue growth of approximately 25% to 29% for 2026, which translates to an expected revenue of between $111 million to $115 million. Given the strong regulatory milestones achieved—such as obtaining Breakthrough Device Designation—Ceribell is well-positioned to capture a significant market opportunity exceeding $1.5 billion.
In conclusion, while Ceribell shows promising revenue momentum and strategic advancements in product offerings, investors should weigh these against the rising operating costs and net losses. A cautious approach, possibly waiting for clearer indicators of sustained profitability, could be prudent while observing Ceribell’s operational efficiency as it scales in the coming quarters.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Fourth Quarter 2025 & Recent Highlights
- Reported total revenue of $24.8 million in the fourth quarter of 2025, a 34% increase compared to the same period in 2024
- Delivered total revenue of $89.1 million for the full year of 2025, a 36% increase over the prior year
- Ended the year with 647 total active accounts
- Achieved gross margin of 87% in the fourth quarter of 2025 and 88% for the full year of 2025
- Received FDA 510(k) clearance for first-of-its-kind continuous monitoring solution for delirium
- Received FDA 510(k) clearance for use of Clarity algorithm for neonates, becoming the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults
- Received FDA Breakthrough Device Designation for first-in-class large vessel occlusion (LVO) stroke detection and monitoring solution
“2025 was a milestone year for Ceribell,” said co-founder and CEO Jane Chao, Ph.D. “We accelerated adoption across new and existing accounts, broadened the age range of our seizure detection algorithm to include pediatric and neonatal populations, and achieved critical regulatory milestones, unlocking incremental market opportunities that we believe exceed $1.5 billion. As we enter the new year, we believe these accomplishments position us well to drive continued growth and advance our long-term vision of making EEG a new vital sign.”
Fourth Quarter 2025 Financial Results
Total revenue in the fourth quarter of 2025 was $24.8 million, a 34% increase from $18.5 million in the fourth quarter of 2024. The increase was primarily driven by expansion into new accounts and continued growth in adoption within the company’s active account base. Product revenue for the fourth quarter of 2025 was $18.8 million, representing an increase of 33% from $14.1 million in the fourth quarter of 2024. Subscription revenue for the fourth quarter of 2025 was $6.0 million, representing an increase of 37% from $4.4 million in the fourth quarter of 2024.
Gross profit in the fourth quarter of 2025 was $21.6 million, compared to $16.2 million for the fourth quarter of 2024. Gross margin for the fourth quarter of 2025 was 87%, compared to 88% for the same period in 2024.
Operating expenses in the fourth quarter of 2025 were $36.2 million, compared to $29.1 million for the fourth quarter of 2024, representing an increase of 24%. The increase in operating expenses was primarily attributable to investments in the company’s commercial organization, increased headcount to support the growth of the business, legal expenses, and expenses related to operating as a public company.
Net loss in the fourth quarter of 2025 was $13.5 million, or $0.36 net loss per share, compared to a net loss of $12.6 million, or $0.40 net loss per share, for the same period in 2024.
Full Year 2025 Financial Results
Total revenue in the full year of 2025 was $89.1 million, a 36% increase from $65.4 million in the full year of 2024. The increase was primarily driven by expansion into new accounts and continued growth in adoption within the company’s active account base. Product revenue for the full year of 2025 was $67.3 million, representing an increase of 34% from $50.1 million in the full year of 2024. Subscription revenue for the full year of 2025 was $21.7 million, representing an increase of 41% from $15.4 million in the full year of 2024.
Gross profit in the full year of 2025 was $78.3 million, compared to $56.8 million for the full year of 2024. Gross margin for the full year of 2025 was 88% compared to 87% for the same period in 2024.
Operating expenses in the full year of 2025 were $136.7 million, compared to $96.5 million for the full year of 2024, representing an increase of 42%. The increase in operating expenses was primarily attributable to investments in the company’s commercial organization, increased headcount to support the growth of the business, legal expenses, and expenses related to operating as a public company.
Net loss in the full year of 2025 was $53.4 million, or $1.46 net loss per share, compared to a net loss of $40.5 million, or $3.39 net loss per share, for the same period in 2024.
Cash, cash equivalents, and marketable securities totaled $159.3 million as of December 31, 2025.
2026 Financial Outlook
Ceribell expects revenue for the full year 2026 to be in the range of $111 million to $115 million, representing growth of approximately 25% to 29% over the company’s prior year revenue.
Webcast and Conference Call Details
Ceribell will host a conference call today, February 24, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its fourth quarter and full year 2025 financial results. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 9394689. A live and archived webcast of the event will be available on the “Investor Relations” section of the Ceribell website at https://investors.ceribell.com/.
Forward-Looking Statements
Except where otherwise noted, the information contained in this earnings release and the related attachments is as of February 24, 2026. We assume no obligation to update any forward-looking statements contained in this earnings release and the related attachments as a result of new information or future events or developments. This earnings release and the related attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; business plans, strategy, goals and prospects; and expectations for our products. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Ceribell’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market acceptance and adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; the manufacturing of a substantial number of our product components and their assembly in China and Vietnam; product defects or complaints and related liability; the complexity, timing, expense, and outcomes of clinical studies, legal matters and regulatory compliance; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; and other risks and uncertainties, including those described under the heading “Risk Factors” in our Registration Statement on Form S-1, Annual Report on Form 10-K, and other reports filed with the U.S. Securities and Exchange Commission (“SEC”). These filings, when made, are available on the Investor Relations section of our website at https://investors.ceribell.com/ and on the SEC’s website at https://sec.gov/.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Investor Contacts
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com
Media Contact
Brian Price
Press@ceribell.com
| Ceribell, Inc. | ||||||||||||||||
| Statements of Operations and Comprehensive Loss | ||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| Three months ended December 31, | Year ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue | ||||||||||||||||
| Product revenue | $ | 18,784 | $ | 14,147 | $ | 67,335 | $ | 50,079 | ||||||||
| Subscription revenue | 6,000 | 4,387 | 21,728 | 15,365 | ||||||||||||
| Total revenue | 24,784 | 18,534 | 89,063 | 65,444 | ||||||||||||
| Cost of revenue | ||||||||||||||||
| Product cost of goods sold | 2,956 | 2,136 | 10,128 | 8,209 | ||||||||||||
| Subscription cost of revenue | 185 | 160 | 661 | 485 | ||||||||||||
| Total cost of revenue | 3,141 | 2,296 | 10,789 | 8,694 | ||||||||||||
| Gross profit | 21,643 | 16,238 | 78,274 | 56,750 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 5,062 | 3,913 | 19,143 | 13,562 | ||||||||||||
| Sales and marketing | 19,058 | 15,243 | 73,082 | 49,055 | ||||||||||||
| General and administrative | 12,119 | 9,966 | 44,451 | 33,842 | ||||||||||||
| Total operating expenses | 36,239 | 29,122 | 136,676 | 96,459 | ||||||||||||
| Loss from operations | (14,596 | ) | (12,884 | ) | (58,402 | ) | (39,709 | ) | ||||||||
| Interest expense | (462 | ) | (499 | ) | (1,890 | ) | (1,992 | ) | ||||||||
| Change in fair value of warrant liability | — | (1,079 | ) | — | (1,496 | ) | ||||||||||
| Other income, net | 1,531 | 1,886 | 6,880 | 2,742 | ||||||||||||
| Loss, before provision for income taxes | (13,527 | ) | (12,576 | ) | (53,412 | ) | (40,455 | ) | ||||||||
| Provision for income tax expense | — | — | — | — | ||||||||||||
| Net loss | $ | (13,527 | ) | $ | (12,576 | ) | $ | (53,412 | ) | $ | (40,455 | ) | ||||
| Net loss per share attributable to common stockholders: | ||||||||||||||||
| Basic and diluted | (0.36 | ) | (0.40 | ) | (1.46 | ) | (3.39 | ) | ||||||||
| Weighted-average shares used in computing net loss per share attributable to common stockholders: | ||||||||||||||||
| Basic and diluted | 37,218,830 | 31,205,891 | 36,542,048 | 11,949,973 |
| Ceribell, Inc. | ||||||||
| Balance Sheets | ||||||||
| (in thousands, except share and per share data) | ||||||||
| (unaudited) | ||||||||
| December 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 40,476 | $ | 194,370 | ||||
| Marketable securities | 118,785 | — | ||||||
| Accounts receivable, net | 15,053 | 10,878 | ||||||
| Inventory | 7,288 | 6,937 | ||||||
| Contract costs, current | 2,210 | 1,837 | ||||||
| Prepaid expenses and other current assets | 2,906 | 3,250 | ||||||
| Total current assets | 186,718 | 217,272 | ||||||
| Property and equipment, net | 2,030 | 2,313 | ||||||
| Operating lease right-of-use assets | 2,296 | 2,132 | ||||||
| Contract costs, long-term | 1,847 | 1,507 | ||||||
| Other non-current assets | 2,912 | 2,188 | ||||||
| Total assets | $ | 195,803 | $ | 225,412 | ||||
| Liabilities, redeemable convertible preferred stock and stockholders’ deficit | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 2,838 | $ | 1,143 | ||||
| Accrued liabilities | 14,328 | 10,052 | ||||||
| Contract liabilities, current | 101 | 97 | ||||||
| Operating lease liability, current | 1,105 | 1,088 | ||||||
| Other current liabilities | 818 | 609 | ||||||
| Total current liabilities | 19,190 | 12,989 | ||||||
| Long-term liabilities | ||||||||
| Notes payable, long-term | 19,811 | 19,558 | ||||||
| Contract liabilities, long-term | — | 30 | ||||||
| Other liabilities, long-term | 106 | 356 | ||||||
| Operating lease liability, long-term | 1,360 | 1,314 | ||||||
| Total long-term liabilities | 21,277 | 21,258 | ||||||
| Total liabilities | $ | 40,467 | $ | 34,247 | ||||
| Commitments and contingencies | ||||||||
| Stockholders’ deficit | ||||||||
| Preferred stock, $0.001 par value; | ||||||||
| Authorized shares: 10,000,000 and none shares as of December 31, 2025 and December 31, 2024, respectively | ||||||||
| Issued and outstanding shares: none as of December 31, 2025 and December 31, 2024, respectively | — | — | ||||||
| Common stock, $0.001 par value; | ||||||||
| Authorized shares: 500,000,000 as of December 31, 2025 and December 31, 2024, respectively | ||||||||
| Issued and outstanding shares: 37,485,124 and 35,850,606 as of December 31, 2025 and December 31, 2024, respectively | 38 | 36 | ||||||
| Additional paid-in capital | 375,495 | 358,073 | ||||||
| Accumulated other comprehensive income | 159 | — | ||||||
| Accumulated deficit | (220,356 | ) | (166,944 | ) | ||||
| Total stockholders’ deficit | 155,336 | 191,165 | ||||||
| Total liabilities, redeemable convertible preferred stock and stockholders’ deficit | $ | 195,803 | $ | 225,412 |
FAQ**
Given the substantial revenue growth reported by CeriBell Inc. (CBLL) in 2025, what specific strategies or market trends contributed to this 36% increase compared to the previous year?
CeriBell Inc. (CBLL) achieved FDA Breakthrough Device Designation for a new stroke detection solution. How does this approval impact the company's potential market opportunities and competitive positioning?
Despite achieving a 34% revenue increase in Q4 2025, CeriBell Inc. (CBLL) reported a net loss of $13.5 million. What measures is the company implementing to improve profitability in the upcoming fiscal year?
With CeriBell Inc. (CBLL) expecting revenue growth of 25-29% in 2026, what factors could influence their ability to meet this guidance, considering industry competition and their operational challenges?
**MWN-AI FAQ is based on asking OpenAI questions about CeriBell Inc. (NASDAQ: CBLL).
NASDAQ: CBLL
CBLL Trading
-2.64% G/L:
$17.36 Last:
135,798 Volume:
$17.80 Open:
